Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History EXEL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics EXEL

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Exelixis Inc

EXEL
Current price
40.37 USD -0.37 USD (-0.91%)
Last closed 40.74 USD
ISIN US30161Q1040
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 11 009 221 632 USD
Yield for 12 month +80.87 %
1Y
3Y
5Y
10Y
15Y
EXEL
21.11.2021 - 28.11.2021

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. Address: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

41.32 USD

P/E ratio

18.43

Dividend Yield

Financials EXEL

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures EXEL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+2 168 701 000 USD

Last Year

+1 830 208 000 USD

Current Quarter

+555 447 000 USD

Last Quarter

+566 755 000 USD

Current Year

+2 092 485 000 USD

Last Year

+1 757 661 000 USD

Current Quarter

+536 275 000 USD

Last Quarter

+546 790 000 USD
EBITDA 844 281 024 USD
Operating Margin TTM 33.64 %
Price to Earnings 18.43
Return On Assets TTM 18.05 %
PEG Ratio 2.27
Return On Equity TTM 30.22 %
Wall Street Target Price 41.32 USD
Revenue TTM 2 298 921 984 USD
Book Value 7.75 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 30.60 %
Dividend Yield
Gross Profit TTM 2 224 790 016 USD
Earnings per share 2.19 USD
Diluted Eps TTM 2.19 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 358.30 %
Profit Margin 27.99 %

Stock Valuation EXEL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 18.43
Forward PE 20.66
Enterprise Value Revenue 4.54
Price Sales TTM 4.91
Enterprise Value EBITDA 12.36
Price Book MRQ 5.29

Technical indicators EXEL

For 52 weeks

21.82 USD 48.85 USD
50 Day MA 39.90 USD
Shares Short Prior Month 18 723 325
200 Day MA 34.70 USD
Short Ratio 4.90
Shares Short 18 607 983
Short Percent 9.36 %